EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EyePoint Pharmaceuticals Inc
Operating Income
EyePoint Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Operating Income
-$243.4m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-28%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$26.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$16.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$19.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$26.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$29.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
EyePoint Pharmaceuticals Inc
Glance View
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
See Also
What is EyePoint Pharmaceuticals Inc's Operating Income?
Operating Income
-243.4m
USD
Based on the financial report for Dec 31, 2025, EyePoint Pharmaceuticals Inc's Operating Income amounts to -243.4m USD.
What is EyePoint Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-28%
Over the last year, the Operating Income growth was -67%. The average annual Operating Income growth rates for EyePoint Pharmaceuticals Inc have been -46% over the past three years , -46% over the past five years , and -28% over the past ten years .
